Prof. Matthias Ocker represents Tacalyx at the ESMO Congress, September 13–17, 2024.
Part of the Tacalyx team attends the ESMO Congress 2024 in Barcelona, September 13–17. Prof. Matthias Ocker, Head of Experimental Medicine, is available for meetings on Tacalyx's latest data.
Press releases
€11 million from the existing syndicate in a first closing of the seed extension. TCX-201 is selected as first clinical candidate, with a CTA filing planned for 2027.
Scientific presentations
Two posters at the AACR Annual Meeting 2026 in San Diego: the preclinical profile of first clinical candidate TCX-201 (Poster 5631) and TCX-101 as a trispecific T-cell engager (Poster 5584).
Company
Scientific Advisory Board meeting in Berlin, Clinical Advisory Board meeting and AACR Oncology Industry Partnering Event in San Diego, followed by two posters at AACR 2026.